Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Modeling the impact of the Omicron infection wave in Germany

View ORCID ProfileBenjamin F. Maier, View ORCID ProfileAngelique Burdinski, View ORCID ProfileMarc Wiedermann, View ORCID ProfileAnnika H. Rose, View ORCID ProfileMatthias an der Heiden, View ORCID ProfileOle Wichmann, Thomas Harder, View ORCID ProfileFrank Schlosser, View ORCID ProfileDirk Brockmann
doi: https://doi.org/10.1101/2022.07.07.22277391
Benjamin F. Maier
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin F. Maier
  • For correspondence: bfmaier@physik.hu-berlin.de
Angelique Burdinski
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelique Burdinski
Marc Wiedermann
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Wiedermann
Annika H. Rose
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annika H. Rose
Matthias an der Heiden
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthias an der Heiden
Ole Wichmann
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ole Wichmann
Thomas Harder
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Schlosser
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frank Schlosser
Dirk Brockmann
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2Institut für Theoretische Biologie und Integrated Research Institute for the Life-Sciences, Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dirk Brockmann
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND In November 2021, the first case of SARS-CoV-2 “variant of concern” (VOC) B.1.1.529 (“Omicron”) was reported in Germany, alongside global reports of reduced vaccine efficacy against infections with this variant. The potential threat posed by the rapid spread of this variant in Germany remained, at the time, elusive.

METHODS We developed a variant-dependent population-averaged susceptible-exposed-infected-recovered (SEIR) infectious disease model. The model was calibrated on the observed fixation dynamics of the Omicron variant in December 2021, and allowed us to estimate potential courses of upcoming infection waves in Germany, focusing on the corresponding burden on intensive care units (ICUs) and the efficacy of contact reduction strategies.

RESULTS A maximum median incidence of approximately 300 000 (50% PI in 1000: [181,454], 95% PI in 1000: [55,804]) reported cases per day was expected with the median peak occurring in the mid of February 2022, reaching a cumulative Omicron case count of 16.5 million (50% PI in mio: [11.4, 21.3], 95% PI in mio: [4.1, 27.9]) until Apr 1, 2022. These figures were in line with the actual Omicron waves that were subsequently observed in Germany with respective peaks occurring in mid February (peak: 191k daily new cases) and mid March (peak: 230k daily new cases), cumulatively infecting 14.8 million individuals during the study period. The model peak incidence was observed to be highly sensitive to variations in the assumed generation time and decreased with shorter generation time. Low contact reductions were expected to lead to containment. Early, strict, and short contact reductions could have led to a strong “rebound” effect with high incidences after the end of the respective non-pharmaceutical interventions. Higher vaccine uptake would have led to a lower outbreak size. To ensure that ICU occupancy remained below maximum capacity, a relative risk of requiring ICU care of 10%–20% was necessary (after infection with Omicron vs. infection with Delta).

CONCLUSIONS We expected a large cumulative number of infections with the VOC Omicron in Germany with ICU occupancy likely remaining below capacity nevertheless, even without additional non-pharmaceutical interventions. Our estimates were in line with the retrospectively observed waves. The results presented here informed legislation in Germany. The methodology developed in this study might be used to estimate the impact of future waves of COVID-19 or other infectious diseases.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

B.F.M. is supported as an Add-on Fellow for Interdisciplinary Life Science by the Joachim Herz Stiftung.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used openly available human data that were originally located at https://github.com/robert-koch-institut/SARS-CoV-2_Infektionen_in_Deutschland, https://github.com/robert-koch-institut/SARS-CoV-2-Sequenzdaten_aus_Deutschland, https://github.com/robert-koch-institut/COVID-19-Impfungen_in_Deutschland, https://zenodo.org/record/6470799 or available upon request.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are contained in the manuscript or available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 10, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Modeling the impact of the Omicron infection wave in Germany
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Modeling the impact of the Omicron infection wave in Germany
Benjamin F. Maier, Angelique Burdinski, Marc Wiedermann, Annika H. Rose, Matthias an der Heiden, Ole Wichmann, Thomas Harder, Frank Schlosser, Dirk Brockmann
medRxiv 2022.07.07.22277391; doi: https://doi.org/10.1101/2022.07.07.22277391
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Modeling the impact of the Omicron infection wave in Germany
Benjamin F. Maier, Angelique Burdinski, Marc Wiedermann, Annika H. Rose, Matthias an der Heiden, Ole Wichmann, Thomas Harder, Frank Schlosser, Dirk Brockmann
medRxiv 2022.07.07.22277391; doi: https://doi.org/10.1101/2022.07.07.22277391

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1419)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10295)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1731)
  • Health Policy (789)
  • Health Systems and Quality Improvement (672)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12091)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (492)
  • Occupational and Environmental Health (568)
  • Oncology (1322)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5006)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (525)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)